Stratec SE Stock (DE000STRA555): Q4 2025 Earnings Released April 28, Revenue at EUR 251M

Stratec SE released its full-year 2025 financial results on April 28, 2026, reporting revenue of EUR 251 million, down 2.6% year-over-year, with adjusted EBIT of EUR 25.2 million. Management guided for medium-to-high single-digit sales growth in 2026 and stable dividend ahead of June 24 ex-date.

Stratec SE released its full-year 2025 financial results on April 28, 2026, reporting revenue of EUR 251 million, down 2.6% year-over-year, with adjusted EBIT of EUR 25.2 million at a 10% margin, according to MarketBeat, April 28, 2026. One-time items including a EUR 6.1 million intangible impairment and EUR 4.3 million inventory write-off reduced reported EBIT to EUR 9.1 million, leaving net income slightly negative for the year.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Stratec
• ISIN: DE000STRA555
• Sector/Industry: Medical Technology Equipment
• Headquarters/Country: Birkenfeld, Germany
• Primary Exchange: Frankfurt Stock Exchange
• Trading Currency: EUR
• Last Quarterly Results: Full Year 2025, published April 28, 2026
• Dividend: 0.6621 USD per share, ex-date June 24, 2026

How Stratec SE Makes Money: The Core Business Model

Stratec SE develops and manufactures standard and customized OEM instrument systems for the in vitro diagnostics (IVD) and life sciences industries. The company focuses on mechatronic components and modules integrated into customer systems for clinical chemistry, immunodiagnostics, molecular diagnostics, and point-of-care testing, according to company stock information on stratec.com, accessed April 30, 2026.

Revenue stems primarily from long-term contracts with major diagnostic firms, where Stratec provides complete system solutions including hardware, software, and after-sales services. The business model emphasizes high barriers to entry through proprietary technology in fluid handling, optics, and robotics tailored for high-throughput lab automation.

In the 2025 financial year, consolidated sales held steady despite market challenges, meeting the margin forecast as stated in the annual financial report published April 28, 2026, according to Finanzwire, April 2026.

Stratec SE's Key Revenue and Product Drivers

For full-year 2025, revenue reached EUR 251 million, a 2.6% decline year-over-year or 1.1% on constant currency basis, with adjusted EBIT at EUR 25.2 million yielding a 10% margin, down from 13% in 2024, as reported in the Q4 earnings call highlights dated April 28, 2026, according to MarketBeat, April 28, 2026. Adjusted EBITA stood at EUR 40.6 million with 16.2% margin.

Key drivers include system sales to IVD customers, with new system launches expected to drive recovery. Inventories ended at EUR 130 million, net financial debt at EUR 112 million (net debt/EBITDA 3.3x), and a new EUR 125 million syndicated loan was secured to bolster working capital, per the same earnings call materials.

Management issued 2026 guidance for medium-to-high single-digit sales growth, back-end loaded, followed by 6%-8% growth through 2028 and 10%-12% CAGR from 2028-2030, targeting adjusted EBIT margin of at least 13% by 2028 and 15% by 2030, according to MarketBeat, April 28, 2026.

Industry Trends and Competitive Landscape

The in vitro diagnostics market continues to grow driven by aging populations, rising chronic disease prevalence, and demand for decentralized testing post-COVID. Stratec benefits from partnerships with leading IVD players requiring precision automation for high-volume analyzers.

Competitive pressures include supply chain disruptions and inventory normalization in diagnostics, contributing to Stratec's 2025 revenue dip. The company holds a niche in customized mechatronics, distinguishing it from broader automation providers.

Free float shares represent 59.62%, held by international and national investors, with 40.38% in fixed ownership, supporting stable ownership structure amid sector volatility, per stratec.com investor page.

Why Stratec SE Matters to US Investors

Stratec SE trades over-the-counter in the United States as SRBZF, providing US investors access to European medtech exposure without direct Frankfurt listing requirements. The ADR structure facilitates USD-denominated dividends, such as the upcoming 0.6621 USD per share payable June 26, 2026 to shareholders of record June 25, according to Futunn, April 28, 2026.

With EUR trading and exposure to global diagnostics firms including US-based customers, Stratec offers currency diversification but introduces EUR/USD FX risk for American portfolios. The stock traded at EUR 17.62 on April 29, 2026 at 17:35 CET on the Frankfurt exchange, per stratec.com, April 29, 2026.

US investors track Stratec for its role in the IVD supply chain, paralleling domestic players amid growing demand for automated lab systems in precision medicine.

Which Investor Profile Fits Stratec SE – and Which Does Not?

Long-term investors focused on medtech innovation and OEM partnerships may monitor Stratec for recovery potential post-2025 normalization. Those seeking exposure to diagnostics automation without pure-play end-market volatility find alignment with its B2B model.

Short-term traders sensitive to quarterly swings or high inventory levels might avoid, given back-end loaded 2026 guidance and ongoing working capital discipline. High-growth tech seekers may overlook the steady, contract-driven profile.

Dividend-oriented profiles note the stable payout commitment despite 2025 challenges, with ex-date June 24, 2026 approaching.

Risks and Open Questions for Stratec SE

Persistent elevated inventories at EUR 130 million and net debt at EUR 112 million (3.3x EBITDA) pressure liquidity, despite the new EUR 125 million syndicated loan secured in 2025, as detailed in the April 28, 2026 earnings call per MarketBeat. Supply chain risks in medtech components remain relevant.

Customer concentration in IVD exposes to sector cycles, as seen in 2025 revenue decline. Execution on new system launches critical for 2026 growth targets.

FX volatility impacts reported USD dividends for US holders, alongside regulatory hurdles in diagnostics approvals.

Key Events and Outlook for Investors

Stratec SE reaffirmed stable dividends with ex-date June 24, 2026, paying 0.6621 USD per share on June 26, 2026, providing near-term catalyst amid recovery positioning. Medium-to-high single-digit sales growth guided for 2026, with multi-year targets to 2030.

New system launches underpin back-end loaded 2026 ramp, targeting adjusted EBIT margin expansion to 13% by 2028.

What to Watch Next

• June 24, 2026: Ex-dividend date
• 2026 H2: New system launches and sales recovery
• 2028: Adjusted EBIT margin target of 13%

Conclusion

Stratec SE's April 28, 2026 release of 2025 results highlighted revenue of EUR 251 million and adjusted EBIT of EUR 25.2 million amid one-time charges, setting the stage for 2026 recovery. Guidance points to growth acceleration and margin expansion through 2030, with dividend stability via June 24 ex-date. US investors gain medtech exposure through SRBZF amid EUR FX considerations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.